Connor, Clark & Lunn Investment Management Ltd. - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.

Quarter-by-quarter ownership
Connor, Clark & Lunn Investment Management Ltd. ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$3,842,854
+36.1%
542,776
+35.3%
0.02%
+42.9%
Q2 2023$2,824,511
-2.6%
401,209
+15.4%
0.01%
-12.5%
Q1 2023$2,899,076
+808.5%
347,611
+1150.6%
0.02%
+700.0%
Q4 2022$319,098
-78.8%
27,796
-69.9%
0.00%
-71.4%
Q1 2022$1,503,000
+96.7%
92,430
+91.2%
0.01%
+75.0%
Q2 2021$764,000
-37.6%
48,352
-92.1%
0.00%
-63.6%
Q1 2020$1,224,000
+100.0%
611,934
+244.8%
0.01%
+175.0%
Q4 2019$612,000
+684.6%
177,482
+992.0%
0.00%
Q1 2018$78,000
-57.6%
16,253
-56.7%
0.00%
-100.0%
Q4 2017$184,000
-28.1%
37,528
-23.2%
0.00%
-50.0%
Q3 2017$256,000
-32.3%
48,855
-63.3%
0.00%
-33.3%
Q2 2016$378,000
-33.7%
133,005
-34.0%
0.00%
-25.0%
Q1 2016$570,000
-73.3%
201,573
-2.4%
0.00%
-77.8%
Q4 2015$2,132,000
-21.5%
206,573
-13.3%
0.02%
-18.2%
Q3 2015$2,716,000
+101.0%
238,273
+163.3%
0.02%
+83.3%
Q2 2015$1,351,000
-6.8%
90,498
-43.6%
0.01%0.0%
Q1 2015$1,450,000
-44.0%
160,598
-24.6%
0.01%
-42.9%
Q4 2014$2,591,000
+56.4%
213,098
+25.8%
0.02%
+61.5%
Q3 2014$1,657,000
-18.3%
169,398
+13.4%
0.01%
-7.1%
Q2 2014$2,029,000
-67.1%
149,398
-71.7%
0.01%
-68.9%
Q1 2014$6,167,000528,0980.04%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q2 2022
NameSharesValueWeighting ↓
VHCP Management II, LLC 6,071,142$38,430,00018.43%
RTW INVESTMENTS, LP 4,078,895$25,819,0009.72%
VHCP Management, LLC 1,155,104$7,312,0007.86%
RA Capital Management 2,989,795$18,925,0002.68%
DLD Asset Management, LP 1,258,700$7,967,0002.61%
Avoro Capital Advisors LLC 1,631,502$10,327,0002.09%
Ghost Tree Capital, LLC 1,150,000$7,280,0001.75%
GREAT POINT PARTNERS LLC 725,000$4,589,0000.94%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,237,734$20,495,0000.84%
Baker Brothers Advisors 10,963,944$69,402,0000.68%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders